Has Polycythemia Vera (PV) become a disease of the middle-aged?

What is the average age of someone diagnosed with PV in 2022? Is the disease being detected earlier? The prevalence of these mutations (JAK2, CALR) are more than anticipated.

It's time to think of Polycythemia Vera (MPNs) as a disease affecting middle age patients.

Based on data from LLS and other sources, shows ET being diagnosed slightly younger than PV patients. Both PV and ET are diseases of the middle-aged.

The video examines whether polycythemia vera (PV), a blood disorder, has become more common among middle-aged people. Although previously considered a disease primarily affecting older individuals, with a median diagnosis age of around 54, more patients in their 20s, 30s, and 40s are now being diagnosed. This could be due to earlier detection through increased screening and testing or changes in disease epidemiology. A population study on clonal hematopoiesis of indeterminate potential (CHIP) found that around 3% of individuals had a JAK2 mutation, associated with PV. This suggests that there may be more cases of PV than previously thought, although further research is necessary. Dr. Abu-Zeinah notes that the shift in diagnosis age is likely related to improved testing and disease detection over time.